These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 30096458)

  • 1. BMI1 and PTEN are key determinants of breast cancer therapy: A plausible therapeutic target in breast cancer.
    M JR; S V
    Gene; 2018 Dec; 678():302-311. PubMed ID: 30096458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog.
    Paranjape AN; Balaji SA; Mandal T; Krushik EV; Nagaraj P; Mukherjee G; Rangarajan A
    BMC Cancer; 2014 Oct; 14():785. PubMed ID: 25348805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy.
    Griffith J; Andrade D; Mehta M; Berry W; Benbrook DM; Aravindan N; Herman TS; Ramesh R; Munshi A
    Oncol Rep; 2017 Apr; 37(4):2382-2390. PubMed ID: 28260023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Participation of BMI-1 protein in cancer.
    Zaczek A; Jóźwiak P; Krześlak A
    Postepy Hig Med Dosw (Online); 2017 Sep; 71(0):811-824. PubMed ID: 28931748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERα inhibits epithelial-mesenchymal transition by suppressing Bmi1 in breast cancer.
    Wei XL; Dou XW; Bai JW; Luo XR; Qiu SQ; Xi DD; Huang WH; Du CW; Man K; Zhang GJ
    Oncotarget; 2015 Aug; 6(25):21704-17. PubMed ID: 26023734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulating BMI1 expression via miRNAs promote Mesenchymal to Epithelial Transition (MET) and sensitizes breast cancer cell to chemotherapeutic drug.
    Patel N; Garikapati KR; Makani VKK; Nair AD; Vangara N; Bhadra U; Pal Bhadra M
    PLoS One; 2018; 13(2):e0190245. PubMed ID: 29394261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic roles of Bmi1 and its therapeutic inhibition by histone deacetylase inhibitor in tongue cancer.
    Li Z; Wang Y; Yuan C; Zhu Y; Qiu J; Zhang W; Qi B; Wu H; Ye J; Jiang H; Yang J; Cheng J
    Lab Invest; 2014 Dec; 94(12):1431-45. PubMed ID: 25286028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of Bmi1 in breast cancer stem cells suppresses tumor growth and proliferation.
    Srinivasan M; Bharali DJ; Sudha T; Khedr M; Guest I; Sell S; Glinsky GV; Mousa SA
    Oncotarget; 2017 Jun; 8(24):38731-38742. PubMed ID: 28418883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors.
    Bommi PV; Dimri M; Sahasrabuddhe AA; Khandekar J; Dimri GP
    Cell Cycle; 2010 Jul; 9(13):2663-73. PubMed ID: 20543557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-31 is a transcriptional target of histone deacetylase inhibitors and a regulator of cellular senescence.
    Cho JH; Dimri M; Dimri GP
    J Biol Chem; 2015 Apr; 290(16):10555-67. PubMed ID: 25737447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hsp90α Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2.
    Lee YC; Chang WW; Chen YY; Tsai YH; Chou YH; Tseng HC; Chen HL; Wu CC; Chang-Chien J; Lee HT; Yang HF; Wang BY
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28914785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
    Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
    Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timosaponin A-III inhibits oncogenic phenotype via regulation of PcG protein BMI1 in breast cancer cells.
    Gergely JE; Dorsey AE; Dimri GP; Dimri M
    Mol Carcinog; 2018 Jul; 57(7):831-841. PubMed ID: 29528145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects and mechanism of microRNA‑218 against lung cancer.
    Chen Y; Yang JL; Xue ZZ; Cai QC; Hou C; Li HJ; Zhao LX; Zhang Y; Gao CW; Cong L; Wang TZ; Chen DM; Li GS; Luo SQ; Yao Q; Yang CJ; Zhu QS; Cao CH
    Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33179084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial-mesenchymal transition and cancer stemness: the Twist1-Bmi1 connection.
    Wu KJ; Yang MH
    Biosci Rep; 2011 Dec; 31(6):449-55. PubMed ID: 21919891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of BMI1 in the Initiation, Progression, and Treatment of Hepatocellular Carcinoma.
    Wang R; Fan H; Sun M; Lv Z; Yi W
    Technol Cancer Res Treat; 2022; 21():15330338211070689. PubMed ID: 35072573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer.
    Sun L; Burnett J; Gasparyan M; Xu F; Jiang H; Lin CC; Myers I; Korkaya H; Liu Y; Connarn J; He H; Zhang N; Wicha MS; Sun D
    Oncotarget; 2016 Aug; 7(32):51408-51422. PubMed ID: 27285982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells.
    Maiti A; Qi Q; Peng X; Yan L; Takabe K; Hait NC
    Int J Oncol; 2019 Jul; 55(1):116-130. PubMed ID: 31059004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MUC1-C activates BMI1 in human cancer cells.
    Hiraki M; Maeda T; Bouillez A; Alam M; Tagde A; Hinohara K; Suzuki Y; Markert T; Miyo M; Komura K; Ahmad R; Rajabi H; Kufe D
    Oncogene; 2017 May; 36(20):2791-2801. PubMed ID: 27893710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YB-1 transforms human mammary epithelial cells through chromatin remodeling leading to the development of basal-like breast cancer.
    Davies AH; Reipas KM; Pambid MR; Berns R; Stratford AL; Fotovati A; Firmino N; Astanehe A; Hu K; Maxwell C; Mills GB; Dunn SE
    Stem Cells; 2014 Jun; 32(6):1437-50. PubMed ID: 24648416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.